Galderma provides progress update regarding RelabotulinumtoxinA regulatory submission in the United States Press release
Galderma reports strong start to the year, delivering first quarter 2026 net sales of 1.473 billion USD, growing 25.5% at constant currency Press release
Galderma buys back shares worth CHF 232 million in the context of accelerated bookbuild offering Press release
Galderma delivers record 2025 results with net sales of 5.207 billion USD, up 17.7% at constant currency, and Core EBITDA of 1.211 billion USD, growing 18.9% at constant currency Press release
Galderma delivers record net sales of 3.737 billion USD in the first nine months of 2025 and 15.0% year-on-year growth at constant currency, raises full-year guidance Press release
Galderma delivers record first half 2025 net sales of 2.448 billion USD and 12.2% year-on-year growth at constant currency, raises full-year top-line guidance Press release
Galderma buys back shares worth CHF 233 million in the context of accelerated bookbuild offering Press release
